Goldman Sachs
ACRS icon

Goldman Sachs’s Aclaris Therapeutics ACRS Stock Holding History

Goldman Sachs’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.21M Sell
588,691
-43,811
-7% -$148K ﹤0.01% 4454
2025
Q4 		$1.9M Sell
632,502
-323,549
-34% -$818K ﹤0.01% 4637
2025
Q3 		$1.82M Buy
956,051
+799,479
+511% +$1.39M ﹤0.01% 4571
2025
Q2 		$222K Sell
156,572
-399,381
-72% -$540K ﹤0.01% 5608
2025
Q1 		$851K Buy
555,953
+127,366
+30% +$272K ﹤0.01% 4816
2024
Q4 		$1.06M Buy
428,587
+127,031
+42% +$316K ﹤0.01% 4779
2024
Q3 		$347K Sell
301,556
-615,064
-67% -$754K ﹤0.01% 5235
2024
Q2 		$1.01M Buy
916,620
+770,808
+529% +$906K ﹤0.01% 4417
2024
Q1 		$181K Sell
145,812
-375,068
-72% -$447K ﹤0.01% 5141
2023
Q4 		$547K Buy
520,880
+248,059
+91% +$757K ﹤0.01% 4699
2023
Q3 		$1.87M Sell
272,821
-116,965
-30% -$999K ﹤0.01% 3820
2023
Q2 		$4.04M Buy
389,786
+93,144
+31% +$843K ﹤0.01% 3285
2023
Q1 		$2.4M Sell
296,642
-50,656
-15% -$643K ﹤0.01% 3719
2022
Q4 		$5.47M Sell
347,298
-74,949
-18% -$1.21M ﹤0.01% 3081
2022
Q3 		$6.65M Buy
422,247
+14,358
+4% +$226K ﹤0.01% 2885
2022
Q2 		$5.69M Buy
407,889
+149,430
+58% +$2.09M ﹤0.01% 3013
2022
Q1 		$4.46M Buy
258,459
+37,267
+17% +$508K ﹤0.01% 3464
2021
Q4 		$3.22M Sell
221,192
-219,902
-50% -$3.33M ﹤0.01% 3815
2021
Q3 		$7.94M Buy
441,094
+115,819
+36% +$1.86M ﹤0.01% 2942
2021
Q2 		$5.71M Buy
325,275
+204,693
+170% +$4.65M ﹤0.01% 3215
2021
Q1 		$3.04M Buy
120,582
+94,275
+358% +$1.84M ﹤0.01% 3579
2020
Q4 		$170K Hold
26,307
– – ﹤0.01% 5144
2020
Q3 		$68K Sell
26,307
-8,805
-25% -$19.7K ﹤0.01% 5146
2020
Q2 		$57K Buy
35,112
+11,026
+46% +$14.8K ﹤0.01% 5057
2020
Q1 		$25K Sell
24,086
-21,623
-47% -$29.4K ﹤0.01% 5112
2019
Q4 		$86K Buy
45,709
+3,767
+9% +$6.24K ﹤0.01% 5065
2019
Q3 		$46K Sell
41,942
-119,270
-74% -$169K ﹤0.01% 5049
2019
Q2 		$353K Buy
161,212
+64,376
+66% +$351K ﹤0.01% 4542
2019
Q1 		$580K Sell
96,836
-27,944
-22% -$185K ﹤0.01% 4353
2018
Q4 		$922K Buy
124,780
+29,342
+31% +$302K ﹤0.01% 4007
2018
Q3 		$1.39M Buy
95,438
+26,337
+38% +$451K ﹤0.01% 3842
2018
Q2 		$1.38M Sell
69,101
-30,321
-30% -$560K ﹤0.01% 3867
2018
Q1 		$1.74M Buy
99,422
+27,810
+39% +$589K ﹤0.01% 3694
2017
Q4 		$1.77M Sell
71,612
-21,143
-23% -$515K ﹤0.01% 3889
2017
Q3 		$2.39M Buy
92,755
+12,727
+16% +$341K ﹤0.01% 3816
2017
Q2 		$2.17M Buy
80,028
+45,305
+130% +$1.23M ﹤0.01% 3771
2017
Q1 		$1.03M Buy
+34,723
New +$1M ﹤0.01% 4346

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs's ACRS Position: Q1 2026 in Review

Goldman Sachs reduced its Aclaris Therapeutics (ACRS) stake by 6.9% in Q1 2026, selling an estimated $148K and leaving 588,691 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4454.

Goldman Sachs first reported a position in ACRS in Q1 2017 and has held it in 37 quarters since. The position peaked at $7.94M in Q3 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Goldman Sachs held 588,691 shares of Aclaris Therapeutics worth $2.21M as of Q1 2026.
  • Goldman Sachs sold 43,811 Aclaris Therapeutics shares in Q1 2026, an estimated $148K.
  • Aclaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4454 holding.
  • Goldman Sachs first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Goldman Sachs's Aclaris Therapeutics position peaked at $7.94M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.